Study to Evaluate the Efficacy and Safety of Sirolimus in Subjects With Metastatic, Mismatch Repair Deficient Solid Tumors After Immunotherapy

Stopped Following discussion with the Cancer Center the PI elected to terminate the study.

Conditions

• Metastatic dMMR Solid Cancer
• Solid Tumor
• Cancer
• Metastatic Solid Tumor

Interventions

• DRUG: Sirolimus 2mg Tablet

Sponsor

Albert Einstein College of Medicine